CryoPort (CYRX)
(Delayed Data from NSDQ)
$16.81 USD
+0.43 (2.63%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $16.81 0.00 (0.00%) 6:18 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.81 USD
+0.43 (2.63%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $16.81 0.00 (0.00%) 6:18 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Zacks News
Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
CryoPort (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -59.38% and 1.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy CryoPort, Inc. (CYRX) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Hub Group (HUBG) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Hub Group (HUBG) delivered earnings and revenue surprises of 3.85% and 0.68%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Expeditors International (EXPD) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Expeditors International (EXPD) delivered earnings and revenue surprises of -7.20% and 5.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 21st
by Zacks Equity Research
ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.
CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -68% and 0.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Daseke (DSKE) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Daseke (DSKE) delivered earnings and revenue surprises of -70.83% and 3.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Hub Group (HUBG) Beats Q2 Earnings Estimates
by Zacks Equity Research
Hub Group (HUBG) delivered earnings and revenue surprises of 2.13% and 6.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of 11.11% and 1.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Trinity Industries (TRN) Misses Q1 Earnings Estimates
by Zacks Equity Research
Trinity Industries (TRN) delivered earnings and revenue surprises of -78.13% and 10.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will CryoPort, Inc. (CYRX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -14.29% and 4.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
C.H. Robinson Worldwide (CHRW) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
C.H. Robinson (CHRW) delivered earnings and revenue surprises of -23.70% and 9.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Signs New Partnership With Cryoport
by Zacks Equity Research
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.
CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -15.38% and 13.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Schneider National (SNDR) Q3 Earnings Top Estimates
by Zacks Equity Research
Schneider National (SNDR) delivered earnings and revenue surprises of 4.48% and 2.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) Stock Jumps 10.5%: Will It Continue to Soar?
by Zacks Equity Research
CryoPort, Inc. (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Can CryoPort, Inc. (CYRX) Climb 36% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CryoPort, Inc. (CYRX) points to a 36.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -13.33% and 0.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Daseke (DSKE) Q2 Earnings Lag Estimates
by Zacks Equity Research
Daseke (DSKE) delivered earnings and revenue surprises of -36.84% and 9.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?